“South Africa has officially launched Lenacapavir, a revolutionary HIV prevention injection administered only twice a year, marking a turning point in the country’s fight against HIV. The rollout across 360 public health facilities is expected to protect millions, reduce stigma, and accelerate progress toward ending AIDS as a public health threat by 2030.”
On 24 July 2026, South Africa entered a new era in its battle against HIV with the official launch of Lenacapavir, a long‑acting injectable drug that requires only two doses per year. President Cyril Ramaphosa described the rollout as a “historic turning point” in national healthcare, emphasizing that the innovation represents hope, science, and resilience in the face of one of the country’s greatest public health challenges.
Background: HIV in South Africa
South Africa continues to carry one of the world’s heaviest HIV burdens, with over 8 million people living with HIV and thousands of new infections annually. Despite decades of progress with antiretroviral therapy (ART) and oral pre‑exposure prophylaxis (PrEP), adherence challenges, stigma, and accessibility gaps have hindered prevention efforts.
What is Lenacapavir?
- Type: Long‑acting HIV prevention drug (PrEP).
- Dosage: One injection every six months.
- Mechanism: Provides continuous protection against HIV infection by blocking viral replication.
- Advantages: Reduces the burden of daily pill adherence, offers discreet administration, and expands prevention choices.
National Rollout Strategy
- Facilities: 360 public health centers across six provinces.
- Target Groups: Adolescent girls, young women, sex workers, and men who have sex with men—groups disproportionately affected by HIV.
- Distribution: Initial batch of 37,920 doses arrived in April 2026.
- Goals: Reach 1 million people by 2027, with a broader target of 3 million citizens within three years.
Government and Global Support
The rollout is supported by the Global Fund, the Children’s Investment Fund Foundation, and the African Union, reflecting international recognition of South Africa’s leadership in HIV prevention. Ramaphosa emphasized that every infection prevented is “a family preserved, a life protected.”
Impact on Public Health
- Reduced Stigma: Unlike oral PrEP pills, which often carry social stigma, Lenacapavir’s discreet injection method encourages uptake.
- Improved Adherence: Twice‑yearly dosing eliminates the daily burden of pill-taking.
- Expanded Choices: Complements existing tools like condoms and oral PrEP, strengthening prevention strategies.
- Alignment with Global Goals: Supports the UNAIDS 2030 target to end AIDS as a public health threat.
Expert Opinions
- Treatment Action Campaign Chairperson Sibongile Tshabalala noted that the injection’s discreet nature will likely increase acceptance among vulnerable groups.
- Healthcare professionals hailed the drug as one of the most significant HIV prevention advances in years.
Challenges Ahead
- Supply Chain: Ensuring consistent nationwide distribution.
- Education: Informing communities about the benefits and safety of Lenacapavir.
- Equity: Guaranteeing access for rural and marginalized populations.
- Monitoring: Tracking uptake and effectiveness to meet ambitious targets.
Conclusion
The launch of Lenacapavir marks a milestone in South Africa’s healthcare journey, offering hope to millions and reinforcing the nation’s commitment to ending HIV/AIDS. With strong political will, international support, and scientific innovation, South Africa is poised to lead the world in HIV prevention breakthroughs.
